
    
      This is a randomized, open-label, positive-control, dose-escalation Phase 1b trial in 60
      patients with chronic HBV infection to determine the safety, preliminary efficacy, and
      pharmacokinetics (PK) of QL-007 after administration over 28 days of multiple oral doses in a
      fasted state at the following planned dose levels: 200, 400, and then 600 mg.
    
  